Last reviewed · How we verify
Single target immunomodulation
At a glance
| Generic name | Single target immunomodulation |
|---|---|
| Sponsor | Erasmus Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TheraSphere With Durvalumab and Tremelimumab for HCC (PHASE2)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies (PHASE1)
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (NA)
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers (PHASE2)
- Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma (PHASE2)
- Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single target immunomodulation CI brief — competitive landscape report
- Single target immunomodulation updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI